Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies

Tektonidou, Maria G., Laskari, Katerina, Panagiotakos, Demosthenes B., Moutsopoulos, Haralampos M.·2009·Arthritis Care & Research
DOI 10.1002/art.24232

Cited by (356)

Items 101–200 of 356

  1. Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
    Marco Capecchi, Maria Abbattista, Alessandro Ciavarella, Mario Uhr, Cristina Novembrino, Ida Martinelli · 2022 · Journal of Clinical Medicine
  2. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study
    Stéphane Zuily, Véronique Regnault, Françis Guillemin, P. Kaminsky, Anne‐Christine Rat, Thomas Lecompte, Denis G. Wahl · 2013 · Thrombosis Research
  3. Grossesse et syndrome des antiphospholipides
    Nathalie Costedoat-Chalumeau, G. Guettrot-Imbert, Véronique Le Guern, Gaëlle Leroux, D u Le Thi Huong, B. Wechsler, Nathalie Morel, D. Vauthier-Brouzes, Marc Dommergues, Alain Cornet et al. · 2012 · La Revue de Médecine Interne
  4. Management of Recurrent Thrombosis in Antiphospholipid Syndrome
    Cecilia Nalli, Laura Andréoli, Cinzia Casu, Anǵela Tincani · 2014 · Current Rheumatology Reports
  5. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study
    Michele Iudici, Serena Fasano, Luisa Gabriele Falcone, Ilenia Pantano, GIOVANNI LA MONTAGNA, Sergio Migliaresi, Gabriele Valentini · 2016 · Rheumatology
  6. Management of cardiovascular complications in systemic lupus erythematosus
    Carly Skamra, Rosalind Ramsey‐Goldman · 2010 · International Journal of Clinical Rheumatology
  7. Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response
    Sabrina da Silva Saraiva, Isadora Custódio, Bruna de Moraes Mazetto, Marina Pereira Colella, Erich Vinícius De Paula, Simone Appenzeller, Joyce Annichino-Bizzachi, Fernanda Andrade Orsi · 2015 · Thrombosis Research
  8. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’
    Vittorio Pengo, Guillermo Ruiz‐Irastorza, Gentian Denas, Laura Andréoli, Munther A. Khamashta, Anǵela Tincani · 2011 · Autoimmunity Reviews
  9. Dyslipidaemia in patients with lupus nephritis
    Yip Boon Chong, Desmond Y. H. Yap, COLIN SO TANG, Tak Mao Chan · 2011 · Nephrology
  10. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus
    Demir, Selcan, Li, Jessica, Magder, Laurence S, Petri, Michelle · 2021 · Rheumatology
  11. Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome
    Íñigo Les, Guillermo Ruiz‐Irastorza, Munther A. Khamashta · 2012 · Seminars in Thrombosis and Hemostasis
  12. New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis
    Alina Casian, Shirish R Sangle, David P. D’Cruz · 2018 · Autoimmunity Reviews
  13. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies
    Toshiyuki Watanabe, Kenji Oku, Olga Amengual, Ryo Hisada, Koichiro Ohmura, I. Nakagawa, Haruki Shida, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda et al. · 2017 · Lupus
  14. Thrombosis in systemic lupus erythematosus: risk and protection
    Paula Isabel Burgos, Graciela S. Alarcón · 2009 · Expert Review of Cardiovascular Therapy
  15. Treatment of antiphospholipid syndrome beyond anticoagulation
    Chrisanna Dobrowolski, Doruk Erkan · 2018 · Clinical Immunology
  16. Antiphospholipid syndrome: a clinical perspective
    Yu Zuo, Hui Shi, Chun Li, Jason S. Knight · 2020 · Chinese Medical Journal
  17. Haralampos M. Moutsopoulos: A lifetime in autoimmunity
    Pierre Youinou · 2010 · Journal of Autoimmunity
  18. Catastrophic antiphospholipid syndrome and pregnancy
    Robert M. Silver · 2017 · Seminars in Perinatology
  19. Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus
    Jaqueline Cristina de Amorim, Renan Bazuco Frittoli, Danilo Pereira, Mariana Postal, Sérgio San Juan Dertkigil, Fabiano Reis, Lilian TL Costallat, Simone Appenzeller · 2019 · Expert Review of Clinical Immunology
  20. Transient ischemic attack and stroke in systemic lupus erythematosus
    Homa Timlin, Michelle Petri · 2013 · Lupus
  21. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
    Élisabeth Pasquier, Luc de Saint Martin, Gisèle Marhic, Céline Chauleur, Caroline Bohec, Florence Bretelle, V. Lejeune, Jacob Hannigsberg, Geneviève Plu‐Bureau, Virginie Cogulet et al. · 2019 · BMJ Open
  22. Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome
    Yiannis Ioannou, Anisur Rahman · 2010 · Lupus
  23. What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?
    Tzu‐Fei Wang, Wendy Lim · 2016 · Hematology
  24. Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study
    Stylianos Panopoulos, Κonstantinos Thomas, Georgios A. Georgiopoulos, Dimitrios T. Boumpas, Christina G. Katsiari, George K Bertsias, Alexandros A. Drosos, Kyriaki A. Boki, Theodoros Dimitroulas, Alexandros Garyfallos et al. · 2020 · Rheumatology
  25. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy
    Jiing–Chyuan Luo, Full‐Young Chang, Tseng‐Shing Chen, Yee‐Yung Ng, Han‐Chieh Lin, Ching‐Liang Lu, CHIH‐YEN CHEN, Hsiao‐Yi Lin, SHOU‐DONG LEE · 2009 · British Journal of Clinical Pharmacology
  26. Treatment of antiphospholipid syndrome
    Massimo Radin, Irene Cecchi, Elena Rubini, Silvia Grazietta Foddai, Alice Barinotti, Elisa Menegatti, Dario Roccatello, Savino Sciascia · 2020 · Clinical Immunology
  27. Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease
    Ozan Ünlü, Doruk Erkan · 2017 · Annual Review of Medicine
  28. Management of Antiphospholipid Syndrome
    Amine Ghembaza, David Saadoun · 2020 · Biomedicines
  29. Accelerated Atherosclerosis and Management of Cardiovascular Risk in Autoimmune Rheumatic Diseases: An Updated Review
    Paschalis Karakasis, Dimitrios Patoulias, Panagiotis Stachteas, Eleftheria Elmina Lefkou, Theodoros Dimitroulas, Nikolaos Fragakis · 2023 · Current Problems in Cardiology
  30. A Review of 32 Free Flaps in Patients with Collagen Vascular Disorders
    Theresa Y. Wang, Joseph M. Serletti, Sharon L. Kolasinski, David W. Low, Stephen J. Kovach, Liza C. Wu · 2012 · Plastic & Reconstructive Surgery
  31. β2‐Glycoprotein I‐Dependent Anti‐Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus
    Chen‐Ying Wang, I‐Tsu Chyuan, Yali Wang, Mark Yen‐Ping Kuo, Ching‐Wen Chang, King‐Jean Wu, Ping‐Ning Hsu, Toshiyuki Nagasawa, Nawarat Wara-aswapati, Yiwen Chen · 2015 · Journal of Periodontology
  32. Autoimmunity and Recurrent Pregnancy Losses
    Ricard Cervera, Juan Balasch · 2009 · Clinical Reviews in Allergy & Immunology
  33. The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus
    Sandra Gofinet Pasoto, Vilma dos Santos Trindade Viana, Eloísa Bonfá · 2014 · Expert Review of Clinical Immunology
  34. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    G. W. Naerr, P. Rein, C. Saely, H. Drexel · 2016 · Vascular pharmacology
  35. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
    Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Kimito Kawahata · 2019 · Internal Medicine
  36. Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort
    Hui Shi, Jialin Teng, Yue Sun, Xinyao Wu, Qiongyi Hu, Hong-lei Liu, Xiaobing Cheng, Yufeng Yin, Junna Ye, Pojen P. Chen et al. · 2017 · Clinical Rheumatology
  37. Treatment of systemic lupus erythematosus
    Kathryn McKeon, Simon Jiang · 2020 · Australian Prescriber
  38. Prevention and management of co-morbidities in SLE
    Tanmayee Bichile, Michelle Petri · 2014 · La Presse Médicale
  39. Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis
    Paschalis Karakasis, Eleftheria Elmina Lefkou, Konstantinos Pamporis, Vasileios Nevras, Konstantinos I. Bougioukas, Anna‐Bettina Haidich, Nikolaos Fragakis · 2023 · Current Problems in Cardiology
  40. Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: “Pros” and “Cons”
    Fulvia Ceccarelli, Cecilia Beatrice Chighizola, Guido Finazzi, Pier Luigi Meroni, Guido Valesini · 2011 · Autoimmunity Reviews
  41. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I
    Dawn M. Wahezi, Ilowite Nt, Wu Xx, Leonie Pelkmans, Bas de Laat, Laura Eve Schanberg, JH Rand, for the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators · 2013 · Lupus
  42. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?
    Ara D. Metjian, Wendy Lim · 2009 · Hematology
  43. Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10‐Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission
    Nikolaos Papazoglou, Petros Paul Sfikakis, Maria G. Tektonidou · 2024 · Arthritis & Rheumatology
  44. Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento
    Rafael Cáliz, Petra Díaz del Campo Fontecha, María Galindo-Izquierdo, Francisco Javier López Longo, María Ángeles Martínez Zamora, Amparo Santamaría, Olga Amengual Pliego, María José Cuadrado Lozano, María Paloma Delgado Beltrán, Loreto Carmona et al. · 2019 · Reumatología Clínica
  45. Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome
    Eleonora Friedberg, Philipp Wohlfarth, Ana Iris Schiefer, Cathrin Skrabs, Winfried Franz Pickl, Nina Worel, Philipp Bernhard Staber, Ulrich Jaeger, Cihan Ay · 2024 · Journal of Thrombosis and Haemostasis
  46. Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders
    Patricia M. Woo · 2009 · Current Opinion in Rheumatology
  47. Prevention of thrombosis in antiphospholipid syndrome
    Wendy Lim · 2016 · Hematology
  48. The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome
    Del Ross, Teresa, Ruffatti, Amelia, Cuffaro, Serena, Tonello, Marta, Calligaro, Antonia, Favaro, Maria, Facchinetti, Myriam, Hoxha, Ariela, Punzi, Leonardo · 2015 · Thrombosis Research
  49. Systemic lupus erythematosus: a clinical update
    Kathryn Connelly, Eric Francis Morand · 2021 · Internal Medicine Journal
  50. Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies
    Manuel Urra, Shannon Lyons, Corina Gabriela Teodosiu, Richard M. Burwick, Anuja Java · 2024 · Kidney International Reports
  51. Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome
    G. Urbanski, Antoine Caillon, Caroline Poli, Gilles Kauffenstein, Marc-Antoine Bégorre, Laurent Loufrani, Daniel Henrion, Cristina C. Belizna · 2018 · PLoS ONE
  52. Targeted therapy in antiphospholipid syndrome
    Savino Sciascia, Munther A. Khamashta, David P. D’Cruz · 2014 · Current Opinion in Rheumatology
  53. Antiphospholipid syndrome: an update for clinicians and scientists
    Vreede, Andrew P., Bockenstedt, Paula L., Knight, Jason S. · 2017 · Current Opinion in Rheumatology
  54. Guía de práctica clínica para el lupus eritematoso sistémico: recomendaciones para el abordaje clínico general
    María M. Trujillo‐Martín, Íñigo Rúa-Figueroa Fernández de Larrinoa, Guillermo Ruiz‐Irastorza, José María Pego‐Reigosa, José Mario Sabio, Pedro Guillermo Serrano-Aguilar · 2016 · Medicina Clínica
  55. How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores
    Kenji Oku, Olga Amengual, Shinsuke Yasuda, Tatsuya Atsumi · 2017 · Current Rheumatology Reports
  56. Loss of antiphospholipid antibody positivity post-thrombosis in SLE
    Muznay Khawaja, Laurence S. Magder, DANIEL W. GOLDMAN, Michelle Petri · 2020 · Lupus Science & Medicine
  57. Acute Myocardial Infarction in Autoimmune Rheumatologic Disease: A Nationwide Analysis of Clinical Outcomes and Predictors of Management Strategy
    Mohamed Mohamed, Edward Roddy, Lina Ya’qoub, Phyo Kyaw Myint, Mirvat A. Alasnag, M. Chadi Alraies, Lorna Elise Clarson, Toby Helliwell, Christian David Mallen, David Lee Fischman et al. · 2020 · Mayo Clinic Proceedings
  58. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus
    Ippei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Yoshino Inoue, Masanobu Ueno, Yoshiya Tanaka · 2018 · International Journal of Rheumatic Diseases
  59. Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer
    Britney R. Niemann, Amanda Puleo, Conley Stout, Justin Markel, Brian A. Boone · 2022 · Pharmaceutics
  60. Primary prevention in antiphospholipid antibody carriers
    MT Bertero · 2012 · Lupus
  61. Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study
    Alexis F. Guédon, Jennifer Catano, Laure Ricard, Charlotte Laurent, Claire DE MOREUIL, G. Urbanski, Sophie Deriaz, Grigoris Gerotziafas, Ismaı̈l Elalamy, Alexandra Audemard‐Verger et al. · 2022 · Arthritis Research & Therapy
  62. Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome
    Signe Aakjær, Elisabeth M. Bendstrup, Per Ivarsen, Line Bille Madsen · 2017 · Respiratory Medicine Case Reports
  63. Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE
    Stylianos Panopoulos, George C Drosos, George D. Konstantonis, Petros Paul Sfikakis, Maria G. Tektonidou · 2023 · Lupus Science & Medicine
  64. Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?
    Giuseppe Alvise Ramirez, Ian J. Mackie, Susanna Nallamilli, Tatiana Costa Pires, Rachel Moll, Charis Pericleous, David Alan Isenberg, Hannah Cohen, Maria Efthymiou · 2020 · Rheumatology
  65. Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus
    Christina Dicke, Katharina Holstein, Sonja Schneppenheim, Rita Dittmer, Reinhard Schneppenheim, Carsten Bokemeyer, Christof Iking‐Konert, Ulrich Budde, Florian Peter Länger · 2014 · Experimental Hematology and Oncology
  66. Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review
    Karen Pesqueda-Cendejas, Melissa Rivera-Escoto, Mónica R. Meza-Meza, Bertha Campos-López, Isela Parra‐Rojas, Margarita Montoya‐Buelna, Ulises De la Cruz-Mosso · 2023 · Nutrients
  67. An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus
    Ryo Hisada, Tatsuya Atsumi · 2023 · Biomolecules
  68. The Metabolic Spectrum of Venous Thrombotic Disorders Found on PET/CT
    Vladimir Sopov, Hanna Bernstine, Dorit Stern, Nikolay Yefremov, Jacob Sosna, David Groshar · 2009 · American Journal of Roentgenology
  69. Antiphospholipid Antibodies and Renal Outcomes in Patients with Lupus Nephritis
    Yuki Tsuruta, Keiko Uchida, Mitsuyo Itabashi, Wako Yumura, Kosaku Nitta · 2009 · Internal Medicine
  70. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study
    Li Su, Zhigang Qi, Shaochen Guan, Lian Wei, Yi Zhao · 2022 · Frontiers in Immunology
  71. The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus
    Veronica Venturelli, Ana Mafalda Abrantes, Anisur Rahman, David Alan Isenberg · 2024 · Rheumatology
  72. Broad Concepts in Management of Systemic Lupus Erythematosus
    VAIDEHI R. CHOWDHARY · 2017 · Mayo Clinic Proceedings
  73. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study
    Laure Ricard, Charlotte Laurent, Matthias Papo, Sophie Deriaz, Jennifer Catano, Sonia Alamowitch, Gilles Kayem, François Chasset, Claire DE MOREUIL, J.J. Boffa et al. · 2021 · Joint Bone Spine
  74. Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults
    Marco Bernardi, Luigi Spadafora, Silvia Andaloro, Alessandra Piscitelli, Giovanni Fornaci, Chiara Intonti, Alberto Emanuele Fratta, Chieh-En Hsu, Karol Kaziród-Wolski, Theodora Metsovitis et al. · 2024 · Journal of Clinical Medicine
  75. Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes
    Can Huang, Yufang Ding, Zhen Chen, Lijun Wu, Wei Wei, Cheng Zhao, Min Yang, Shudian Lin, Qian Wang, Xinping Tian et al. · 2025 · BMC Medicine
  76. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus
    Ippei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Akio Kawabe, Yusuke Miyazaki, Yoshino Inoue et al. · 2020 · International Journal of Rheumatic Diseases
  77. Hydroxychloroquine : une nouvelle approche thérapeutique des manifestations thrombotiques du syndrome des antiphospholipides
    Jean Szymezak, Annick Ankri, Anne‐Marie Fischer, Luc Darnige · 2010 · La Revue de Médecine Interne
  78. Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention
    Antonella Tufano, Anna Guida, Matteo Nicola Dario Di Minno, Angela Maria De Gregorio, Anna Maria Cerbone, Giovanni Di Minno · 2010 · Nutrition Metabolism and Cardiovascular Diseases
  79. Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management
    María M. Trujillo‐Martín, Íñigo Rúa-Figueroa Fernández de Larrinoa, Guillermo Ruiz‐Irastorza, José María Pego‐Reigosa, José Mario Sabio, Pedro Guillermo Serrano-Aguilar · 2016 · Medicina Clínica (English Edition)
  80. Prevention of Pregnancy Complications in Antiphospholipid Syndrome
    Andreas Czwalinna, Frauke Bergmann · 2020 · Hämostaseologie
  81. Autoimmune diseases
    Sara Harsini, Nima Rezaei · 2023 · Elsevier eBooks
  82. Deciphering the clinical significance of longitudinal antiphospholipid antibody titers
    Cecilia Beatrice Chighizola, Rohan Willis, Gabriella Maioli, Savino Sciascia, Laura Andréoli, Olga Amengual, Massimo Radin, Maria Gerosa, Tatsuya Atsumi, Guilherme Ramires de Jesús et al. · 2024 · Autoimmunity Reviews
  83. Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?
    Kimberly Legault, Amaia Ugarte, Mark Andrew Crowther, Guillermo Ruiz‐Irastorza · 2016 · Current Rheumatology Reports
  84. Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells
    Tomomi Aizawa, Tadaatsu Imaizumi, Koji Hirono, Shojiro Watanabe, Koji Tsugawa, Hiroshi Tanaka · 2018 · Clinical and Experimental Nephrology
  85. Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre
    Giuseppe Barilaro, Emmanuel Coloma, Chafik Alejandro Chacur, Carlo Della Rocca, Albert Pérez-Isidro, Estíbaliz Ruiz‐Ortiz, Odette Viñas, Dolors Tàssies Penella, Joan Carles Reverter, Alícia Molina Andújar et al. · 2022 · Autoimmunity Reviews
  86. Management of non‐renal manifestations of systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements
    Nuntana Kasitanon, Laniyati Hamijoyo, Meng Tao Li, Kenji Oku, Sandra Navarra, Yoshiya Tanaka, Chi Chiu Mok · 2022 · International Journal of Rheumatic Diseases
  87. Risk factors for thrombotic events in Korean patients with systemic lupus erythematosus
    Dong-Jin Park, Chang-Seok Yoon, Sung‐Eun Choi, Haimuzi Xu, Ji‐Hyoun Kang, Shin‐Seok Lee · 2021 · Scientific Reports
  88. Traitement du syndrome des anticorps antiphospholipides
    David Saadoun, J.C. Pietté, Denis G. Wahl, Nathalie Costedoat-Chalumeau · 2012 · La Revue de Médecine Interne
  89. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study
    Jie Chen, Shuhui Sun, Qingran Yan, Chunde Bao, Qiong Fu · 2016 · Clinical Rheumatology
  90. Antiphospholipidsyndrom
    Christof Specker, Rebecca Fischer‐Betz, Thomas Dörner · 2020 · Zeitschrift für Rheumatologie
  91. New therapeutic targets for the antiphospholipid syndrome
    Charis Pericleous, Yiannis Ioannou · 2010 · Expert Opinion on Therapeutic Targets
  92. Hydroxychloroquine as an important immunomodulator: a novel insight into an old drug
    Katarzyna Krystyna Pawlak-Buś, Piotr Leszczyński · 2024 · Polskie Archiwum Medycyny Wewnętrznej
  93. Treatment of thrombotic antiphospholipid syndrome in adults and children
    Jacqueline A. Madison, Alí Duarte‐García, Yu Zuo, Jason S. Knight · 2020 · Current Opinion in Rheumatology
  94. Current management of antiphospholipid syndrome-related thrombosis
    Dolores Puente, Gonzalo Pombo, Ricardo R Forastiero · 2009 · Expert Review of Cardiovascular Therapy
  95. A novel antiphospholipid antibody agent?
    Beverley Jane Hunt · 2010 · Blood
  96. Antiphospholipid Syndrome
    Ewa Maria Wysokinska, Thomas L. Ortel · 2019 · Elsevier eBooks
  97. Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies
    Zeinab Saleh, Emily C. Somers, Vivian Romero, Wendy Marder · 2025 · American Journal of Obstetrics and Gynecology
  98. Pregnancy outcomes in patients with systemic lupus erythematosus compared to a high‐risk tertiary cohort and to standard population from the Austrian birth registry
    Klára Rosta, Florian Heinzl, Valerie Kuczwara, Stefanie Schindler, Veronica Falcone, Anja Catic, Marina Riedmann, Hermann Leitner, Elisabeth Simader, Valentin Ritschl et al. · 2024 · Acta Obstetricia Et Gynecologica Scandinavica
  99. Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome
    Natee Sirinvaravong, Mary Carolina Rodriguez Ziccardi, Soumya Patnaik, Mahek Kishor Shah, Gustavo Fernandez, Jose-Nitram Aliling, Alexander Rubin · 2018 · Oxford Medical Case Reports
  100. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital
    Yohei Hosokawa, Hiroshi Oiwa · 2020 · Internal Medicine